• Iridex is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the for treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Since 2015, more than 150,000 patients have been treated with Iridex’s MicroPulse® Transscleral Laser Therapy using the MicroPulse P3® Delivery Device. In 2020, the footplate of the MicroPulse P3 Delivery Device was enhanced to allow it to deliver greater stability, visualization, coupling, and fit. MicroPulse TLT is a non-incisional procedure that substantially reduces IOP for a broad range of glaucoma patients. The procedure can be used for primary open-angle, closed-angle, and refractory glaucoma. It can be performed before, in combination with, or after other glaucoma treatments, making it a very versatile tool. Learn more at iridex.com/micropulsep3